Information Provided By:
Fly News Breaks for November 9, 2016
TSRO, HRTX
Nov 9, 2016 | 09:07 EDT
Cowen analyst Boris Peaker lowered his price target on Heron Therapeutics (HRTX) to $40 from $47 following the company's Q3 results. The analyst expects a slow sales ramp for Sustol due to competition, reimbursement dynamics, and Tesaro's (TSRO) early experience with its launch of Varubi. Peaker maintained his Outperform rating on Heron Therapeutics shares.
News For HRTX;TSRO From the Last 2 Days
There are no results for your query HRTX;TSRO